Intravenous immunoglobulin (IVIg) with methylprednisolone pulse therapy for motor impairment of neuralgic amyotrophy: Clinical observations in 10 cases

Internal Medicine

Volumn 51, Issue 12, 2012, Pages 1493-1500

  Naito, Ko Suke ^a   Fukushima, Kazuhiro ^a   Suzuki, Seiko ^b   Kuwahara, Motoi ^b   Morita, Hiroshi ^a   Kusunoki, Susumu ^b   Ikeda, Shu Ichi ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Brachial plexus; Intravenous immunoglobulin; Methylprednisolone pulse therapy; Neuralgic amyotrophy; Parsonage Turner syndrome

Indexed keywords

GANGLIOSIDE GD 1A; GANGLIOSIDE GD 1B; GANGLIOSIDE GD3; GANGLIOSIDE GM1; GANGLIOSIDE GM2; GANGLIOSIDE GM3; GANGLIOSIDE GQ 1B; GANGLIOSIDE GT 1B; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; METHYLPREDNISOLONE;

ADULT; AGED; ARTICLE; BRACHIAL PLEXUS NEUROPATHY; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; DRUG PULSE THERAPY; ELECTROMYOGRAPHY; ELECTROPHYSIOLOGY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; LATENT PERIOD; LEUKOCYTE COUNT; MALE; MOTOR DYSFUNCTION; MOTOR NERVE CONDUCTION; MULTIPLE CYCLE TREATMENT; MUSCLE ACTION POTENTIAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SIDE EFFECT;

ADULT; AGED; BRACHIAL PLEXUS NEURITIS; ELECTROPHYSIOLOGICAL PHENOMENA; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOMODULATION; MALE; METHYLPREDNISOLONE; MIDDLE AGED; NEURALGIA; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84862980950     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.51.7049     Document Type: Article

References (21)

1. MacDonald BK, Cockerell OC, Sander JW, Shorvon SD. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain: a journal of neurology 123: 665-676, 2000.
2. Beghi E, Kurland LT, Mulder DW, Nicolosi A. Brachial plexus neuropathy in the population of Rochester, Minnesota, 1970-1981. Ann Neurol 18: 320-323, 1985.
3. van Alfen N, van Engelen BG. The clinical spectrum of neuralgic amyotrophy in 246 cases. Brain 129: 438-450, 2006.
4. Collie AM, Landsverk ML, Ruzzo E, et al. Non-recurrent SEPT9 duplications cause hereditary neuralgic amyotrophy. J Med Genet 47: 601-607, 2010.
5. Magee KR, Dejong RN. Paralytic brachial neuritis. Discussion of clinical features with review of 23 cases. JAMA 174: 1258-1262, 1960.
6. England JD, Sumner AJ. Neuralgic amyotrophy: an increasingly diverse entity. Muscle Nerve 10: 60-68, 1987.
7. Cruz-Martinez A, Barrio M, Arpa J. Neuralgic amyotrophy: variable expression in 40 patients. J Peripher Nerv Syst 7: 198-204, 2002.
8. Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscu-lar Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors. J Neurol Sci 124 (Suppl): 96-107, 1994.
9. van Alfen N, van der Werf SP, van Engelen BG. Long-term pain, fatigue, and impairment in neuralgic amyotrophy. Arch Phys Med Rehabil 90: 435-439, 2009.
10. van Eijk JJ, van Alfen N, Berrevoets M, van der Wilt GJ, Pillen S, van Engelen BG. Evaluation of prednisolone treatment in the acute phase of neuralgic amyotrophy: an observational study. J Neurol Neurosurg Psychiatry 80: 1120-1124, 2009.
11. van Alfen N, van Engelen BG, Hughes RA. Treatment for idi-opathic and hereditary neuralgic amyotrophy (brachial neuritis). Cochrane Database Syst Rev CD006976, 2009.
12. Kuhlenbaumer G, Stogbauer F, Timmerman V, De Jonghe P. Diagnostic guidelines for hereditary neuralgic amyotrophy or heredofa-milial neuritis with brachial plexus predilection. On behalf of the European CMT Consortium. Neuromuscul Disord 10: 515-517, 2000.
13. Kusunoki S, Chiba A, Kon K, et al. N-acetylgalactosaminyl GD1a is a target molecule for serum antibody in Guillain-Barre syndrome. Ann Neurol 35: 570-576, 1994.
14. Moriguchi K, Miyamoto K, Takada K, Kusunoki S. Four cases of anti-ganglioside antibody-positive neuralgic amyotrophy with good response to intravenous immunoglobulin infusion therapy. J Neuroimmunol 238: 107-109, 2011.
15. Nobile-Orazio E, Meucci N, Barbieri S, Carpo M, Scarlato G. High-dose intravenous immunoglobulin therapy in multifocal motor neuropathy. Neurology 43: 537-544, 1993.
16. Lott JA, Warren P. Estimation of reference intervals for total protein in cerebrospinal fluid. Clin Chem 35: 1766-1770, 1989.
17. van Alfen N. Clinical and pathophysiological concepts of neuralgic amyotrophy. Nat Rev Neurol 7: 315-322, 2011.
18. Tsao BE, Avery R, Shields RW. Neuralgic amyotrophy precipitated by Epstein-Barr virus. Neurology 62: 1234-1235, 2004.
19. Nakajima M, Fujioka S, Ohno H, Iwamoto K. Partial but rapid recovery from paralysis after immunomodulation during early stage of neuralgic amyotrophy. Eur Neurol 55: 227-229, 2006.
20. Al Masri O, Fathallah W, Quader S. Recovery of tacrolimus-associated brachial neuritis after conversion to everolimus in a pe-diatric renal transplant recipient: case report and review of the literature. Pediatr Transplant 12: 914-917, 2008.
21. Vriesendorp FJ, Dmytrenko GS, Dietrich T, Koski CL. Anti-peripheral nerve myelin antibodies and terminal activation products of complement in serum of patients with acute brachial plexus neuropathy. Arch Neurol 50: 1301-1303, 1993.